In this interview, Dr Angus Thomson (Irimi Company, Lyon, France) discusses effective methods for communicating with patients about their vaccinations, how healthcare professionals (HCPs) can help to counteract disinformation, and additional resources for HCPs and patients.
Interviews available in this series:
- In your opinion, what are the most effective methods of communicating with patients about their vaccinations? (0:50)
- How can HCPs best support their patients with their decision on whether to get vaccinated? (6:35)
- What could HCPs do to help counteract disinformation? (8:49)
- Could you tell us a little about any resources that are available to HCPs to help improve communication with patients, and other HCPs? (12:07)
Disclosures: Dr Angus Thomson is a consultant for UNICEF, and Sabin Vaccine Institute.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Share this Video
Related Videos In Vaccines
The first mass reactive vaccination campaign against hepatitis E in Bentiu, South Sudan: Iza Ciglenecki, EASL 2023
Since 2015, cases of hepatitis E have been reported in the Bentiu camp in South Sudan, Africa, which hosts over 100,000 people displaced from conflict and flooding. The first mass reactive vaccination campaign against hepatitis E using the Hecolin® vaccine, the key findings of the campaign and unanswered questions, are discussed by Dr Iza Ciglenecki […]
The Hecolin® vaccine in the prevention of hepatitis E: Iza Ciglenecki, EASL 2023
A three-dose recombinant vaccine (Hecolin®) against hepatitis E has been licensed in China since 2011. We caught up with Dr Iza Ciglenecki (Médecins Sans Frontières, Geneva, Switzerland) to discuss the prognosis and treatment paradigm for hepatitis E, the challenges associated with optimizing hepatitis E vaccine efficacy and reducing the burden of disease, and what is […]
PHH-1V vaccine compared to BNT162b2 as a SARS-CoV-2 booster vaccine, phase IIb results: Patricia Muñoz García, ECCMID 2023
PHH-1V, a SARS-CoV-2 protein-based heterodimer vaccine was investigated in a phase IIb trial where the immunogenicity and safety of a heterologous booster with PHH-1V was assessed versus a homologous booster with BNT162b2 at 14, 28 and 98 days after vaccine administration. We spoke with Prof. Patricia Muñoz García (Gregorio Marañón General University Hospital, Madrid, Spain) […]
Journal articles and more to your inbox
Get the latest clinical insights from touchINFECTIOUS DISEASESSign me up!